Citi Pharma Ltd. CPHL
Rs 60.35
Vol486,741Updated15:492 Nov 2026
At a Glance
The headline take on CPHL — valuation, income, returns, and efficiency
Consolidated snapshot
Price & Performance
Closing prices across timeframes, returns, and range context
CPHL — Price History
Daily closing series · toggle period below
Key Metrics
Valuation, profitability, structure, and risk in one grid
Dividend History & Yield
Payout track record, yield trend, and upcoming distribution
CPHL has no cash dividend in the trailing 12 months. Its most recent payout was Rs 3.50/share, announced 02 Oct 2025 with book closure from 21 Oct 2025. Annual dividend-per-share history back to 2016 is charted below.
Latest Payout
Dividend Per Share Trend
Payout History
Source: PSX company payouts
| Announced | For Period | Type | Amount | Book Closure |
|---|---|---|---|---|
| 02 Oct 2025 | 30 Jun 2025 (YR) | Cash | Rs 3.50(35%) | 21 Oct 2025 – 27 Oct 2025 |
Financials & Earnings
Income, balance sheet, and key ratios from published accounts
CPHL's market capitalisation stands at Rs 13.88B as of 30 Oct 2026 — down 30.9% over the past 12 months (from Rs 20.09B).
Financial Statements
How CPHL's income and balance sheet have evolved
| PKR Millions | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | Trend |
|---|---|---|---|---|---|---|---|
| Net Sales / Revenue | 14,075.8 | 13,153.52 | 12,409 | 12,397 | 9,780 | 5,795 | |
| Cost of Sales | 11,602.86 | 11,135.91 | 10,823 | 10,890 | 8,428 | 5,015 | |
| Gross Profit | 2,472.94 | 2,017.61 | 1,586 | 1,507 | 1,352 | 780 | |
| Administrative Expenses | 254.51 | 222.11 | 204 | 188 | 266 | 111 | |
| Operating Profit | 1,940.39 | 1,604.25 | 1,206 | 1,167 | 983 | 571 | |
| EBITDA | — | 1,772 | 1,344 | 1,258 | 1,059 | 637 | |
| Other Income | 91.93 | 198.27 | 490 | 292 | 197 | 5 | |
| Financial Charges | 388.77 | 329.67 | 300 | 386 | 71 | 41 | |
| Profit Before Tax | 1,344.52 | 1,354.51 | 1,281 | 957 | 1,033 | 500 | |
| Taxation | 554.18 | 462.47 | 448 | 299 | 397 | 148 | |
| Profit After Tax | 790.33 | 892.04 | 833 | 658 | 636 | 352 | |
| EPS - Basic (Rs) | Rs 3.46 | Rs 3.90 | Rs 3.65 | Rs 2.88 | Rs 2.78 | Rs 1.54 |
All figures in PKR millions from published accounts.
Profitability & Returns
Margins, returns on capital, and earnings per share
Latest · FY25
| Ratio | Value |
|---|---|
| Net profit margin | 6.8% |
| Gross profit margin | 15.3% |
| EBITDA margin | 13.5% |
| EBIT margin | 12.2% |
Net profit margin
Net profit ÷ revenue · %
Financial Health
Coverage, leverage, and the strength of the balance sheet
Latest · FY26
| Ratio | Value |
|---|---|
| Current ratio | 1.25 |
| Quick ratio | 0.54 |
| Cash ratio | 0.04 |
| Asset turnover | 0.77x |
| Effective tax rate | 41.2% |
Current ratio
Current assets ÷ current liabilities
Market cap trajectory
Close × current shares outstanding · current Rs 13.88B
Valuation & Capital Returns
What the market is paying for CPHL, and what it returns to shareholders
Latest · FY26
| Ratio | Value |
|---|---|
| Price to earnings | 17.55x |
| Price to book | 1.28x |
| Price to sales | 0.99x |
Price to earnings
Period-end price ÷ EPS · times
Technical Analysis
Trading signal, moving averages, momentum, and key levels
10-day SMA (Rs 60.11) is below the 30-day SMA (Rs 65.93). RSI at 39 sits in the neutral band.
Moving AverageThe average close over a set window (10/30/200 days) — smooths daily noise to reveal the trend.Read the full guide →
| Period | Value | vs Current | Position |
|---|---|---|---|
| SMA 10 | Rs 60.11 | -0.40% | Above |
| SMA 30 | Rs 65.93 | +9.24% | Below |
| SMA 60 | Rs 69.73 | +15.54% | Below |
| SMA 200 | Rs 76.69 | +27.07% | Below |
At 39, momentum sits within the neutral band (30–70), suggesting balanced buying and selling pressure.
- MACD-2.95
- Signal-3.04
- Histogram+0.09
Leverage Insights
MTS, margin financing, futures open interest, and combined exposure
Leverage Composition
MTS · MFS stacked over the selected window
As of 29 Oct 2026
Futures Blank Sale Insights
Blank sale value vs OI and free float
Settlement Insights
UIN-wise settlement concentration and price context
Metrics and charts over the selected trailing window
Settlement % Trajectory
Solid = UIN settlement % · Dashed = 14-session EMA
As of 30 Oct 2026
Price vs Settlement
Close price (left axis) · UIN settlement % (right axis)
About the Company
Business description, governance, and corporate information
Citi Pharma Limited incorporated as a private limited company in Pakistan under the repealed Companies Ordinance, 1984 on October 08, 2012. The principal activity of the company is manufacturing and sale of pharmaceuticals, medical chemicals and botanical products.
Corporate Information
- RegistrarF.D Registrar Services (Pvt.) Ltd.
- AuditorAslam Malik & Co. Chartered Accountants
- Websitewww.citipharma.com.pk
- Address3-KM, Head Balloki Road, Bhai Pheru, Distt Kasur
- SectorPharmaceuticals
- Financial Year EndJune
Key People
| Name | Role |
|---|---|
RARizwan Ahmad | CEO |
NANadeem Amjad | Chairperson |
MRMuhammad Rasheed Alam | Company Secretary |
Reports & Filings
Recent Announcements
Latest company filings as reported on PSX
Filings and disclosures from the PSX announcement feed
- 02 Nov 2026Report
- 02 Nov 2026Financial Results
- 30 Oct 2026Material Information
- 30 Oct 2026Board MeetingBoard Meeting In Progress
- 28 Oct 2026General Meeting
- 26 Oct 2026Management Change
- 23 Oct 2026Board Meeting
- 19 Oct 2026Material Information
Peers in Pharmaceuticals
How the cohort is moving — same-sector stocks by market cap
CPHL vs Pharmaceuticals sector median
| Metric | CPHL | Sector median |
|---|---|---|
| P/E RatioShare price ÷ earnings per share — the price you pay for each rupee of annual profit. Compare within a sector.Read the full guide → | 17.6x | 12.7x |
| Dividend YieldTrailing-12-month cash dividends ÷ share price. A high yield can signal income — or a falling price.Read the full guide → | — | 2.7% |
| Return on EquityNet profit ÷ shareholders' equity — how hard the company works each rupee investors have put in.Read the full guide → | 7.3% | 16.9% |
| 1-Year Return | -31.6% | -20.1% |
| Market CapitalisationShare price × total shares — the company's full market value, and the basis for index weightings.Read the full guide → | Rs 13.88B | Rs 15.17B |
Pharmaceuticals · sector heat
Why Choose BSL as Your PSX Broker?
Bhayani Securities is an SECP-licensed brokerage and PSX TREC holder with over two decades in Pakistan's stock market. Investors get live prices, research and support in one account.
- Retail Trading
Open a PSX trading account with secure market access and research support.
- Online Trading
Trade on the BSL app with real-time PSX data and portfolio monitoring.
- Margin Financing
Borrow to trade larger positions and increase your buying power.
- Research Reports
Market insights, stock analysis and investing guides from BSL.
- Institutional Services
Research-driven execution, market insights and corporate access for institutions.
- High Net Worth Services
A dedicated senior dealer and preferential rates for portfolios above PKR 2.5 million.
- Trading APIs
Full PSX data, live level-2 market data and sandbox order execution through BSL.
- Roshan Digital Account
Invest in the PSX remotely as an overseas Pakistani.
- Sahulat Account
Start investing with minimal documentation and a fast setup.
- Minor Accounts
Invest for your children and build long-term wealth early.
Frequently Asked Questions
The most common questions investors ask about CPHL
CPHL is trading at Rs 60.35, down 0.64% on the day, within a 52-week range of Rs 56.11–93.99, from the 15-minute snapshot taken at 15:50 PKT. Prices on this page refresh every 15 minutes during market hours; log in to BSL for live quotes.
Citi Pharma Limited incorporated as a private limited company in Pakistan under the repealed Companies Ordinance, 1984 on October 08, 2012. See About the Company on this page for the full profile, management, and corporate information.
CPHL has not declared a cash dividend in the recent PSX record — some companies reinvest earnings instead; see the Financials section. For income ideas, browse the highest dividend yield stocks on PSX.
No upcoming payout is announced yet. The most recent was a payout of Rs 3.50 per share with book closure from 21 Oct 2025. New announcements appear on this page and on the PSX ex-dates calendar.
Yes — Citi Pharma Ltd. is on the PSX's Shariah-compliant (KMI All Shares) list and is a KMI-30 constituent; it also belongs to the KSE-100. Browse all Shariah-compliant PSX stocks.
CPHL trades at 17.6x earnings against a Pharmaceuticals median of 12.7x. The full comparison table and peer list are in the Peers section, or explore the Pharmaceuticals sector page.
Annual reports from FY2025 to FY2026 are linked under Reports & Filings in the About section of this page, sourced from official PSX submissions.
Open a BSL trading account, fund it, and place your CPHL order on the Pakistan Stock Exchange — account opening takes minutes online, with PSX execution, research, and concierge support included.
Quotes and metrics refresh on a regular cadence through the trading day and after the close. For streaming real-time PSX prices and order placement, log in to your BSL account.
Ready to invest in CPHL?
Open a BSL trading account in under 10 minutes
Buy and sell CPHL and every other PSX-listed stock with low commissions, real-time data, and a concierge research desk backing every trade.